LAVA Therapeutics NV expected to post a loss of 33 cents a share - Earnings Preview

Reuters11-12

LAVA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> NV <lvtx.oq> expected to post a loss of 33 cents a share - Earnings Preview </lvtx.oq>

LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a fall in quarterly revenue when it reports results on November 14 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 33 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for LAVA Therapeutics NV is 6.00, above its last closing price of $1.85.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Jun. 30 2024	-0.37	-0.36	-0.31	Beat	13.9
Mar. 31 2024	-0.11	-0.12	-0.02	Beat	84
Jan. 1 0001	0.33	-0.12	-0.24	Missed	-92
Sep. 30 2023	-0.49	-0.49	-0.34	Beat	30.6
Jun. 30 2023	-0.47	-0.47	-0.48	Missed	-1.4
Mar. 31 2023	-0.52	-0.52	-0.53	Missed	-1.9
Dec. 31 2022		-0.63	-0.57	Beat	10.1
Jan. 1 0001	0.00	-0.14	0.04	Beat	128.7

This summary was machine generated November 12 at 13:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482700670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482700670","market":"us","top_or_hot":-1,"title":"LAVA Therapeutics NV  expected to post a loss of 33 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>LAVA <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV <lvtx.oq> expected to post a loss of 33 cents a share - Earnings Preview </lvtx.oq></title></head><body><ul><li><p>LAVA Therapeutics NV <span>LVTX.OQ</span> <span>LVTX.O</span> is expected to show a fall in quarterly revenue when it reports  results on November 14 (estimated) for the period ending September 30 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 33 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for LAVA Therapeutics NV is 6.00, above its last closing price of $1.85. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.37</p></td><td><p>-0.36</p></td><td><p>-0.31</p></td><td><p>Beat</p></td><td><p>13.9</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.11</p></td><td><p>-0.12</p></td><td><p>-0.02</p></td><td><p>Beat</p></td><td><p>84</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>0.33</p></td><td><p>-0.12</p></td><td><p>-0.24</p></td><td><p>Missed</p></td><td><p>-92</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.49</p></td><td><p>-0.49</p></td><td><p>-0.34</p></td><td><p>Beat</p></td><td><p>30.6</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-0.47</p></td><td><p>-0.47</p></td><td><p>-0.48</p></td><td><p>Missed</p></td><td><p>-1.4</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-0.52</p></td><td><p>-0.52</p></td><td><p>-0.53</p></td><td><p>Missed</p></td><td><p>-1.9</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td></td><td><p>-0.63</p></td><td><p>-0.57</p></td><td><p>Beat</p></td><td><p>10.1</p></td></tr><tr><td><p>Jan. 1 0001</p></td><td><p>0.00</p></td><td><p>-0.14</p></td><td><p>0.04</p></td><td><p>Beat</p></td><td><p>128.7</p></td></tr></tbody></table><p>This summary was machine generated November 12 at 13:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAVA Therapeutics NV  expected to post a loss of 33 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAVA Therapeutics NV  expected to post a loss of 33 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ1MW:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>LAVA Therapeutics NV  expected to post a loss of 33 cents a share - Earnings Preview LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a fall in quarterly revenue when it reports  results on ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ1MW:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LVTX","symbol_name":"LAVA Therapeutics N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ1MW:1","article_id":"2482700670","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482700670","pubTimestamp":1731419945,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LAVA Therapeutics NV  expected to post a loss of33cents a share - Earnings Preview LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a fall in quarterly revenue when it reports  results on Novem","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LVTX":"LAVA Therapeutics N.V."},"translate_title":"LAVA Therapeutics NV预计每股亏损33美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LVTX":0.9},"content_text":"LAVA Therapeutics NV  expected to post a loss of 33 cents a share - Earnings Preview LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a fall in quarterly revenue when it reports  results on November 14 (estimated) for the period ending September 30 2024LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 33 cents per share. The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for LAVA Therapeutics NV is 6.00, above its last closing price of $1.85. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Jun. 30 2024-0.37-0.36-0.31Beat13.9Mar. 31 2024-0.11-0.12-0.02Beat84Jan. 1 00010.33-0.12-0.24Missed-92Sep. 30 2023-0.49-0.49-0.34Beat30.6Jun. 30 2023-0.47-0.47-0.48Missed-1.4Mar. 31 2023-0.52-0.52-0.53Missed-1.9Dec. 31 2022-0.63-0.57Beat10.1Jan. 1 00010.00-0.140.04Beat128.7This summary was machine generated November 12 at 13:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482700670"}